Kennelly, S. P., Abdullah, L., Paris, D., Parish, J., Mathura, V., Mullan, M., Crawford, F., Lawlor, B. A., Kenny, R. A.

Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]

Kanagaratnam, Lukshe, Mahmoudi, Rachid, Novella, Jean-Luc, Jolly, Damien, Dramé, Moustapha, Trenque, Thierry

Introduction: Drug prescriptions represent an actionable item in the prevention of adverse drug reactions (ADRs). The aims of this study were to identify risk factors for the occurrence of ADRs, and to describe symptoms and drug interactions. Methods: This was a longitudinal study over a period of 19 months in an acute geriatric ward specializing […]

Grossberg, George T., Manes, Facundo, Allegri, Ricardo F., Gutiérrez-Robledo, Luis Miguel, Gloger, Sergio, Xie, Lei, Jia, X. Daniel, Pejović, Vojislav, Miller, Michael L., Perhach, James L., Graham, Stephen M.

Introduction: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors.; Methods: In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of […]

Farokhnia, Mehdi, Shafiee Sabet, Mehdi, Iranpour, Negar, Gougol, Amirhossein, Yekehtaz, Habibeh, Alimardani, Roozbeh, Farsad, Farzaneh, Kamalipour, Maryam, Akhondzadeh, Shahin

Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]

Emre, Murat, Poewe, Werner, De Deyn, Peter Paul, Barone, Paolo, Kulisevsky, Jaime, Pourcher, Emmanuelle, van Laar, Teus, Storch, Alexander, Micheli, Federico, Burn, David, Durif, Frank, Pahwa, Rajesh, Callegari, Francesca, Tenenbaum, Nadia, Strohmaier, Christine

Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]

Doody, Rachelle S., Raman, Rema, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, He, Feng, Sun, Xiaoying, Thomas, Ronald G., Aisen, Paul S, Siemers, Eric, Sethuraman, Gopalan, Mohs, Richard

Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]

Carrasco, Manuel Martin, Agüera, Luis, Gil, Pedro, Moríñigo, Angel, Leon, Teresa

The objective of this study was to evaluate the prevalence and treatment responsiveness of neuropsychiatric symptoms in patients with mild to moderately severe Alzheimer disease recruited in a naturalistic treatment setting in Spain. All the patients, who matched the prescribing recommendations for donepezil and were able to participate in the study, received donepezil (5 to […]

Barak, Yoram, Plopski, Igor, Tadger, Shelly, Paleacu, Diana

Background: Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer’s disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.; Methods: Inpatients with AD, who had been hospitalized because of […]